RegeneRx Completes Dosing in Phase I Safety Trial
RegeneRx Biopharmaceuticals has completed enrollment and dosing for its Phase Ia clinical trial testing RGN-352 for treating heart attack patients.
The trial tested the safety of escalating doses of the drug in 40 healthy subjects. No significant drug-related adverse events were reported. The drug appeared safe in single doses at low, medium and high concentrations, the company said.
The drug is an injectable formulation of Tβ4, a naturally occurring peptide.